Literature DB >> 26348024

Molecular cytopathology for thyroid nodules: A review of methodology and test performance.

Michiya Nishino1.   

Abstract

Advances in the molecular characterization of thyroid cancers have fueled the development of genetic and gene expression-based tests for thyroid fine-needle aspirations. Collectively, these tests are designed to improve the diagnostic certainty of thyroid cytology. This review summarizes the early published experience with the commercially available versions of these tests: the Afirma Gene Expression Classifier, ThyGenX (formerly miRInform)/ThyraMIR, and ThyroSeq. Key differences in testing approaches and issues regarding test performance and interpretation are also discussed.
© 2015 American Cancer Society.

Entities:  

Keywords:  DNA mutational analysis; fine-needle aspiration biopsy; high-throughput nucleotide sequencing; microarray analysis; molecular diagnostic techniques; thyroid neoplasms

Mesh：

Year:  2015        PMID： 26348024     DOI： 10.1002/cncy.21612

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN： 1934-662X            Impact factor:   5.284


  37 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

2.  European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics.

Authors:  Ralf Paschke; Silvia Cantara; Anna Crescenzi; Barbara Jarzab; Thomas J Musholt; Manuel Sobrinho Simoes
Journal:  Eur Thyroid J       Date:  2017-05-19

Review 3.  Molecular profiling of thyroid nodule fine-needle aspiration cytology.

Authors:  Markus Eszlinger; Lorraine Lau; Sana Ghaznavi; Christopher Symonds; Shamir P Chandarana; Moosa Khalil; Ralf Paschke
Journal:  Nat Rev Endocrinol       Date:  2017-03-31       Impact factor: 43.330

Review 4.  Current methodologies for molecular screening of thyroid nodules.

Authors:  Elisabetta Macerola; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

5.  miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas.

Authors:  Nicla Borrelli; Maria Denaro; Clara Ugolini; Anello Marcello Poma; Mario Miccoli; Paolo Vitti; Paolo Miccoli; Fulvio Basolo
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

6.  A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma.

Authors:  Marialuisa Sponziello; Gabriella Silvestri; Antonella Verrienti; Alessia Perna; Francesca Rosignolo; Chiara Brunelli; Valeria Pecce; Esther Diana Rossi; Celestino Pio Lombardi; Cosimo Durante; Sebastiano Filetti; Guido Fadda
Journal:  Endocrine       Date:  2018-04-26       Impact factor: 3.633

7.  Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.

Authors:  Pablo Valderrabano; Laila Khazai; Marino E Leon; Zachary J Thompson; Zhenjun Ma; Christine H Chung; Julie E Hallanger-Johnson; Kristen J Otto; Kara D Rogers; Barbara A Centeno; Bryan McIver
Journal:  Endocr Relat Cancer       Date:  2017-01-19       Impact factor: 5.678

8.  The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.

Authors:  E Macerola; T Rago; A Proietti; F Basolo; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-04-27       Impact factor: 4.256

Review 9.  Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.

Authors:  Carles Zafon; Juan J Díez; Juan C Galofré; David S Cooper
Journal:  Eur Thyroid J       Date:  2017-03-03

Review 10.  Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods.

Authors:  Guy R Adami; Jessica L Tang; Michael R Markiewicz
Journal:  Oral Oncol       Date:  2017-04-17       Impact factor: 5.337
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.